EyeWorld is the official news magazine of the American Society of Cataract & Refractive Surgery.
Issue link: https://digital.eyeworld.org/i/78716
March 2012 patients with suspected or estab- lished glaucoma," she said. While cataract surgery alone does tend to lower IOP, she said, combined cataract and glaucoma surgery is far more effective at reducing IOP. Steven Mansberger, M.D., pre- sented the results of an analysis con- ducted in the Ocular Hypertension Treatment Study database to evalu- ate the magnitude and duration of IOP reduction following uncompli- cated cataract surgery. "We selected only the eyes that underwent cataract surgery alone and those eyes on no IOP-lowering medica- tions at the time of surgery," he said. A control group consisted of ran- domly selected phakic study sub- jects, also from the observation arm of the study, who did not undergo cataract surgery. He reported a sig- nificant drop in IOP in the eyes un- dergoing cataract surgery, from a pre-op mean of 23.9 mm Hg to 19.8 mm Hg 12 months later. "Approxi- mately 40% of eyes had a sustained IOP reduction of 20% or more at 1 year," he said. "Our next step is to identify those patients most likely to enjoy this benefit before surgery." EW MEETING REPORTER 133 The Ahmed versus Baerveldt Comparison Study Panos Christakis, B.Sc., presented the 3-year results of the ongoing Ahmed versus Baerveldt Comparison study. These two devices work some- what differently, with the Ahmed valve (New World Medical, Rancho Cucamonga, Calif.) containing a flow restrictor designed to open in the range of 8-10 mm Hg, while the Baerveldt implant (Abbott Medical Optics, Santa Ana, Calif.) has no flow restrictor and relies on the formation of an encapsulated bleb around the reservoir for flow imped- ance. While complete success at 3 years was unlikely with either device (4% for Ahmed and 11% for Baerveldt), qualified success (IOP between 5 and 18 with or without medications) reached 45% and 54%, respectively, which were statistically comparable. continued on page 134 The EXTO is the ultimate in easy patient access and exit. Dexta Corporation is is pr oud to intr oduce you to their newest t innovation – the EXTO chair. The EXTO is the first chair to blend two lasers into one smooth, efficient operation. The EXTO chair was designed to fill the growing need of doctors for a safe and stable Lasik surgery platform – with easy patient access and exit. The EXTO chair is the first chair that enables s the physician to blend the Femto and Excimer lasers together – into one smooth operation. the Femto and Excimer rs together – into smooth operation. the leader in patient tioning and the positioning and the O chair is no EXTO chair is no exception. The EXTO sn't r equire a eption. The EXTO doesn't r patient to climb to sit, ft their feet or scooot ent to climb to sit, to lift their feet or scoot into position. Numerous safety featur es minimize accidental movement and ensure patient safety . Dexta has always been eader in patient ta has always been n . Dexta. The ultimate in patient positioning. . Since 1966 Since 1966. Dexta Corporation 962 Kaiser Road Napa, CA 94558 Ph: (707) 255-2454 Fx: (707) 255-8520 See the EXTO in action at: www.dexta.com The EXTO's XYZ joystick control with 1/3000" jog function is the ultimate in precision patient positioning. Call Toll Free: 1-800-733-3982 Email: sales@dexta.com Call Toll Free: 1-800-733-3982 Email: sales@dexta.com